<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35599950</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2451-9936</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of ophthalmology case reports</Title>
          <ISOAbbreviation>Am J Ophthalmol Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Intravitreal brolucizumab as treatment of early onset radiation retinopathy secondary to plaque brachytherapy for choroidal melanoma.</ArticleTitle>
        <Pagination>
          <StartPage>101581</StartPage>
          <MedlinePgn>101581</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">101581</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajoc.2022.101581</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">To describe the efficacy and safety of brolucizumab (Beovu®, Novartis Pharmaceuticals) in a case of cystoid macular edema associated with radiation retinopathy as a result of iodine-125 plaque brachytherapy (PBT) for choroidal melanoma, resistant to treatment with other anti-vascular endothelial growth factor (VEGF) agents.</AbstractText>
          <AbstractText Label="OBSERVATIONS" NlmCategory="UNASSIGNED">A 67-year-old woman with choroidal melanoma in the right eye and best-corrected visual acuity (BCVA) of 20/20, underwent uncomplicated PBT. On post-operative month 7, the patient developed early onset radiation retinopathy. She failed to improve significantly with sub-tenon triamcinolone and 3 injections of intravitreal bevacizumab; BCVA was 20/200. Intravitreal brolucizumab was administered, and one month after, macular edema had resolved completely on optical coherence tomography, and BCVA improved to 20/50. At last follow up, 1 month after the third brolucizumab injection, BCVA was 20/60 and there was sustained resolution of intraretinal fluid. There were no signs of intraocular inflammation, progressive RR or optic neuropathy on exam or fluorescein angiography.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This case suggests a positive effect of brolucizumab in the management of radiation retinopathy following PBT refractory to other anti-VEGF agents. However, one must consider the risk of severe vision loss associated with retinal vasculitis from use of brolucizumab.</AbstractText>
          <CopyrightInformation>© 2022 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Villegas</LastName>
            <ForeName>Natacha C</ForeName>
            <Initials>NC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Stanford University School of Medicine, 2452, Watson Ct, Palo Alto, CA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mishra</LastName>
            <ForeName>Kapil</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Retina Service, Department of Ophthalmology, Stanford University School of Medicine, 2452, Watson Ct, Palo Alto, CA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Steinle</LastName>
            <ForeName>Nathan</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>California Retina Consultants, 525 E Micheltorena St A, Santa Barbara, CA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Wu</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beadle</LastName>
            <ForeName>Beth</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mruthyunjaya</LastName>
            <ForeName>Prithvi</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Stanford University School of Medicine, 2452, Watson Ct, Palo Alto, CA, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Am J Ophthalmol Case Rep</MedlineTA>
        <NlmUniqueID>101679941</NlmUniqueID>
        <ISSNLinking>2451-9936</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anti-VEGF</Keyword>
        <Keyword MajorTopicYN="N">Brolucizumab</Keyword>
        <Keyword MajorTopicYN="N">Choroidal melanoma</Keyword>
        <Keyword MajorTopicYN="N">Cystoid macular edema</Keyword>
        <Keyword MajorTopicYN="N">Radiation retinopathy</Keyword>
      </KeywordList>
      <CoiStatement>Nathan Steinle: Novartis (C). Prithvi Mruthyunjaya: Aura Bioscienes (C), Castle Biosciences (C). The following authors have no financial disclosures, NCV, KM, WL, BB.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>3</Hour>
          <Minute>45</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35599950</ArticleId>
        <ArticleId IdType="pmc">PMC9121253</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ajoc.2022.101581</ArticleId>
        <ArticleId IdType="pii">S2451-9936(22)00327-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Archer D.B., Amoaku W.M., Gardiner T.A. Radiation retinopathy--clinical, histopathological, ultrastructural and experimental correlations. Eye. 1991;5(Pt 2):239–251. doi: 10.1038/eye.1991.39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/eye.1991.39</ArticleId>
            <ArticleId IdType="pubmed">2070883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guyer D.R., Mukai S., Egan K.M., Seddon J.M., Walsh S.M., Gragoudas E.S. Radiation maculopathy after proton beam irradiation for choroidal melanoma. Ophthalmology. 1992;99(8):1278–1285. doi: 10.1016/s0161-6420(92)31832-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0161-6420(92)31832-9</ArticleId>
            <ArticleId IdType="pubmed">1325044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown G.C., Shields J.A., Sanborn G., Augsburger J.J., Savino P.J., Schatz N.J. Radiation retinopathy. Ophthalmology. 1982;89(12):1494–1501. doi: 10.1016/s0161-6420(82)34611-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0161-6420(82)34611-4</ArticleId>
            <ArticleId IdType="pubmed">7162794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seibel I., Vollhardt D., Riechardt A.I., et al.  Influence of Ranibizumab versus laser photocoagulation on radiation retinopathy (RadiRet) - a prospective randomized controlled trial. Graefes Arch Clin Exp Ophthalmol. 2020;258(4):869–878. doi: 10.1007/s00417-020-04618-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00417-020-04618-7</ArticleId>
            <ArticleId IdType="pmc">PMC7575494</ArticleId>
            <ArticleId IdType="pubmed">32112140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shields C.L., Demirci H., Dai V., et al.  Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina. 2005;25(7):868–874. doi: 10.1097/00006982-200510000-00009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00006982-200510000-00009</ArticleId>
            <ArticleId IdType="pubmed">16205566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shields C.L., Khoo C.T.L., Mazloumi M., Mashayekhi A., Shields J.A. Photodynamic therapy for choroidal metastasis tumor control and visual outcomes in 58 cases: the 2019 burnier international ocular pathology society lecture. Ophthalmol Retina. 2020;4(3):310–319. doi: 10.1016/j.oret.2019.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.oret.2019.10.009</ArticleId>
            <ArticleId IdType="pubmed">31953111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finger P.T., Chin K.J., Semenova E.A. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study. Eur J Ophthalmol. 2016;26(1):60–66. doi: 10.5301/ejo.5000670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5301/ejo.5000670</ArticleId>
            <ArticleId IdType="pubmed">26391167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murray T.G., Latiff A., Villegas V.M., Gold A.S. Aflibercept for radiation maculopathy study: a prospective, randomized clinical study. Ophthalmol Retina. 2019;3(7):561–566. doi: 10.1016/j.oret.2019.02.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.oret.2019.02.009</ArticleId>
            <ArticleId IdType="pubmed">31277797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finger P.T., Chin K.J. Intravitreous ranibizumab (lucentis) for radiation maculopathy. Arch Ophthalmol. 2010;128(2):249–252. doi: 10.1001/archophthalmol.2009.376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archophthalmol.2009.376</ArticleId>
            <ArticleId IdType="pubmed">20142553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dugel P.U., Koh A., Ogura Y., et al.  HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. doi: 10.1016/j.ophtha.2019.04.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2019.04.017</ArticleId>
            <ArticleId IdType="pubmed">30986442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witkin A.J., Hahn P., Murray T.G., et al.  Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis. 2020;4(4):269–279. doi: 10.1177/2474126420930863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2474126420930863</ArticleId>
            <ArticleId IdType="pmc">PMC7418897</ArticleId>
            <ArticleId IdType="pubmed">32789284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma A., Kumar N., Parachuri N., et al.  Brolucizumab-foreseeable workflow in the current scenario. Eye. 2021;35(6):1548–1550. doi: 10.1038/s41433-020-01324-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41433-020-01324-w</ArticleId>
            <ArticleId IdType="pmc">PMC8169919</ArticleId>
            <ArticleId IdType="pubmed">33531697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rayess N., Mruthyunjaya P. Anti-vascular endothelial growth factor therapy for radiation retinopathy. Ophthalmic Surg Lasers Imaging Retina. 2020;51(4):S44–S49. doi: 10.3928/23258160-20200401-06.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3928/23258160-20200401-06</ArticleId>
            <ArticleId IdType="pubmed">32348534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horgan N., Shields C.L., Mashayekhi A., et al.  Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: a randomized controlled trial. Ophthalmology. 2009;116(7):1383–1390. doi: 10.1016/j.ophtha.2009.01.051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2009.01.051</ArticleId>
            <ArticleId IdType="pubmed">19481812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang M., Dalvin L.A., Mazloumi M., et al.  Prophylactic intravitreal bevacizumab after plaque radiotherapy for uveal melanoma: analysis of visual acuity, tumor response, and radiation complications in 1131 eyes based on patient Age. Asia Pac J Ophthalmol (Phila). 2020;9(1):29–38. doi: 10.1097/APO.0000000000000271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/APO.0000000000000271</ArticleId>
            <ArticleId IdType="pmc">PMC7004475</ArticleId>
            <ArticleId IdType="pubmed">31990743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seibel I., Hager A., Riechardt A.I., Davids A.M., Böker A., Joussen A.M. Antiangiogenic or corticosteroid treatment in patients with radiation maculopathy after proton beam therapy for uveal melanoma. Am J Ophthalmol. 2016;168:31–39. doi: 10.1016/j.ajo.2016.04.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajo.2016.04.024</ArticleId>
            <ArticleId IdType="pubmed">27163234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan M.A., Mashayekhi A., Shields J.A., Shields C.L. Intravitreal aflibercept as rescue therapy for post-radiation cystoid macular edema resistant to intravitreal bevacizumab: outcomes at 1 year. Ocul Oncol Pathol. 2017;3(4):313–319. doi: 10.1159/000452163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000452163</ArticleId>
            <ArticleId IdType="pmc">PMC5757581</ArticleId>
            <ArticleId IdType="pubmed">29344488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finger P.T., Chin K.J. High-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation retinopathy. Eur J Ophthalmol. 2013;23(6):850–856. doi: 10.5301/ejo.5000333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5301/ejo.5000333</ArticleId>
            <ArticleId IdType="pubmed">23813109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bulirsch L.M., Saßmannshausen M., Nadal J., Liegl R., Thiele S., Holz F.G. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study [published online ahead of print, 2021 Apr 12] Br J Ophthalmol. 2021 doi: 10.1136/bjophthalmol-2020-318672. bjophthalmol-2020-318672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjophthalmol-2020-318672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murray J.E., Gold A.S., Latiff A., Murray T.G. Brolucizumab: evaluation of compassionate use of a complex anti-VEGF therapy. Clin Ophthalmol. 2021;15:4731–4738. doi: 10.2147/OPTH.S339393. Published 2021 Dec 18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OPTH.S339393</ArticleId>
            <ArticleId IdType="pmc">PMC8702983</ArticleId>
            <ArticleId IdType="pubmed">34983996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corradetti G., Corvi F., Juhn A., Sadda S.R. Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab. Am J Ophthalmol Case Rep. 2020;20:100981. doi: 10.1016/j.ajoc.2020.100981. Published 2020 Oct 26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajoc.2020.100981</ArticleId>
            <ArticleId IdType="pmc">PMC7595878</ArticleId>
            <ArticleId IdType="pubmed">33145457</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
